ArticleEMBO molecular medicine2017
Poly-GP in cerebrospinal fluid links
Open access · goldAbstract read
In one paragraph
Article in EMBO molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
8.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Cerebrospinal fluid and blood neurofilament light chain levels in amyotrophic lateral sclerosis and frontotemporal degeneration: A meta-analysis.European journal of neurology · 2024Pooled it
- The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface?Journal of neurology · 2021Pooled it
- Presymptomatic Amyotrophic Lateral Sclerosis: From Early Biomarker Detection to Phenoconversion Prediction.Diagnostics (Basel, Switzerland) · 2026Review
- Review
- Microglial Dysfunction Induced by C9ORF72 Dipeptide Repeat Proteins: Biomarker and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Design considerations for C9orf72 disease prevention trials.Brain : a journal of neurology · 2025Review
- Elevated Cerebrospinal Fluid Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1 in Asymptomatic C9orf72 Hexanucleotide Repeat Expansion Carriers.Annals of neurology · 2025Observational
- Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics.The Lancet. Neurology · 2025Review
- Fluid biomarkers in familial frontotemporal dementia: progress and prospects.Frontiers in neurology · 2025Review
- Unveiling amyotrophic lateral sclerosis complexity: insights from proteomics, metabolomics and microbiomics.Brain communications · 2025Review
- Gaps in biomedical research in frontotemporal dementia: A call for diversity and disparities focused research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- C9orf72-Associated Dipeptide Repeat Expansions Perturb ER-Golgi Vesicular Trafficking, Inducing Golgi Fragmentation and ER Stress, in ALS/FTD.Molecular neurobiology · 2024Article
- A Review of Biomarkers of Amyotrophic Lateral Sclerosis: A Pathophysiologic Approach.International journal of molecular sciences · 2024Review
- Poly-GP accumulation due to C9orf72 loss of function induces motor neuron apoptosis through autophagy and mitophagy defects.Autophagy · 2024Article
- Aberrant protein aggregation in amyotrophic lateral sclerosis.Journal of neurology · 2024Review
- Review
- Fluid biomarkers for amyotrophic lateral sclerosis: a review.Molecular neurodegeneration · 2024Review
- Changes in Digital Speech Measures in Asymptomatic Carriers of Pathogenic Variants Associated With Frontotemporal Degeneration.Neurology · 2024Article
- Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit.Neurology and therapy · 2023Article
- Repeated mild traumatic brain injury triggers pathology in asymptomatic C9ORF72 transgenic mice.Brain : a journal of neurology · 2023Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
22 authors at 10 institutions in 1 country.
Carina LehmerGerman Center for Neurodegenerative Diseases (DZNE) and Munich Cluster for System Neurology (SyNergy), Munich, Germany.
Patrick OecklDepartment of Neurology, Ulm University Hospital, Ulm, Germany.
Jochen H WeishauptDepartment of Neurology, Ulm University Hospital, Ulm, Germany.
Alexander E VolkInstitute of Human Genetics, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Janine Diehl-SchmidDepartment of Psychiatry and Psychotherapy, Technical University of Munich, München, Germany.
Matthias L SchroeterClinic for Cognitive Neurology, University Clinic Leipzig, Leipzig, Germany.
Martin LauerDepartment of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Würzburg, Germany.
Johannes KornhuberDepartment of Psychiatry and Psychotherapy, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
Johannes LevinGerman Center for Neurodegenerative Diseases (DZNE) and Munich Cluster for System Neurology (SyNergy), Munich, Germany.
Klaus FassbenderDepartment of Neurology, Saarland University, Homburg, Germany.
Bernhard LandwehrmeyerDepartment of Neurology, Ulm University Hospital, Ulm, Germany.
German Consortium for Frontotemporal Lobar Degeneration
Martin H SchludiGerman Center for Neurodegenerative Diseases (DZNE) and Munich Cluster for System Neurology (SyNergy), Munich, Germany.
Thomas ArzbergerGerman Center for Neurodegenerative Diseases (DZNE) and Munich Cluster for System Neurology (SyNergy), Munich, Germany.
Elisabeth KremmerInstitute of Molecular Immunology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Munich, Germany.
Andrew FlatleyMonoclonal Antibody Core Facility and Research Group, Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Munich, Germany.
Regina FeederleGerman Center for Neurodegenerative Diseases (DZNE) and Munich Cluster for System Neurology (SyNergy), Munich, Germany.
Petra SteinackerDepartment of Neurology, Ulm University Hospital, Ulm, Germany.
Patrick WeydtDepartment of Neurology, Ulm University Hospital, Ulm, Germany.
Albert C LudolphDepartment of Neurology, Ulm University Hospital, Ulm, Germany.
Dieter EdbauerGerman Center for Neurodegenerative Diseases (DZNE) and Munich Cluster for System Neurology (SyNergy), Munich, Germany dieter.edbauer@dzne.de markus.otto@uni-ulm.de.ORCID 0000-0002-7186-4653
Markus OttoDepartment of Neurology, Ulm University Hospital, Ulm, Germany dieter.edbauer@dzne.de markus.otto@uni-ulm.de.ORCID 0000-0003-4273-4267
German Center for Neurodegenerative Diseases · DEUniversity Hospital Ulm · DEHelmholtz Zentrum München · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DESaarland University · DETechnical University of Munich · DEUniversität Hamburg · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Bonn · DEUniversity Hospital Leipzig · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
The
Indexed as
Amyotrophic Lateral SclerosisBiomarkersC9orf72 ProteinCerebrospinal FluidCross-Sectional StudiesDipeptidesFrontotemporal DementiaGene ExpressionHumansImmunoassayPeptidesRepetitive Sequences, Amino AcidBiomarkersC9orf72 ProteinC9orf72 protein, humanDipeptidesPeptidesamyotrophic lateral sclerosisbiomarkerC9orf72cerebrospinal fluidfrontotemporal dementia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.